Invention Application
- Patent Title: ANTIBODIES CAPABLE OF BINDING TO OX40, VARIANTS THEREOF AND USES THEREOF
-
Application No.: US18660672Application Date: 2024-05-10
-
Publication No.: US20240376221A1Publication Date: 2024-11-14
- Inventor: Kristel Kemper , Maarten van der Kroef , Dennis Verzijl , Andrea Gorlani , Pauline Linda de Goeje , Lars Guelen , David Satijn , Esther C. W. Breij , Ugur Sahin , Sina Fellermeier-Kopf , Maren Köhne
- Applicant: Genmab A/S , BioNTech SE
- Applicant Address: DK Valby; DE Mainz
- Assignee: Genmab A/S,BioNTech SE
- Current Assignee: Genmab A/S,BioNTech SE
- Current Assignee Address: DK Valby; DE Mainz
- Priority: EP23173143.1 20230512,EP23213531.9 20231130
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K39/00 ; A61P35/00 ; C07K16/42
Abstract:
The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
Information query
